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1. Introduction 
Neoadjuvant chemotherapy is introduced in many gynecologic cancers such as cervical and 
ovarian cancer. The aim of using neoadjuvant chemotherapy is to reduce the tumor size 
prior to the principle treatment, either radiation or surgery. The benefit of reducing tumor 
size can increase the operability and decrease the morbidity in many types of gynecologic 
cancers. Besides this, neoadjuvant chemotherapy might control the micro- metastatic disease 
to decrease the distant metastasis (Benedetti-Panici et al., 1998; Buda et al., 2005; Chua, 
2010). On the other hand, in patients who did not respond to chemotherapy, however, the 
administration of neoadjuvant chemotherapy risks delaying the principle treatment. 
In this chapter, literature pertaining to neoadjuvant chemotherapy for gynecologic cancer 
will be presented in five parts, categorized by types of cancers; cervical cancer, ovarian 
cancer, endometrial cancer, vulvar cancer, and vaginal cancer.  
2. Cervical cancer 
Cervical cancer is the third most common malignancy in women worldwide. The 
GLOBOCAN project estimates that there will be 530,000 new cases in 2008. The highest 
incidence is in Africa and Asia. In early stage, the patients may be treated with either 
surgery or radiation therapy depending on preferences of both patient and physician 
(Undurraga et al., 2010). Whereas concurrent chemoradiation is the principle treatment in 
the locally advanced stage, and chemotherapy is the main treatment in advanced stage.  
Neoadjuvant chemotherapy has been investigated in cervical cancer with the aim of 
improving the treatment outcome for over 20 years. This section presents the studies about 
using neoadjuvant chemotherapy in cervical cancer before radiation and surgery.  
2.1 Neoadjuvant chemotherapy before radiation therapy 
The rationale of giving neoadjuvant chemotherapy before radiation therapy included 
reducing tumor volume and radio- sensitizing tumors by decreasing the hypoxic cell 
fraction in large tumors (Movva et al., 2009). However, several randomized trials of such 
treatment revealed no survival advantage compared with radiation therapy alone (Chiara et 
al., 1994; Herod et al., 2000; Lacava et al., 1997; Leborgne et al., 1997; Sundfor et al., 1996; 
Souhami et al., 1991; Symonds, 2000; Tattersall et al., 1992; Tattersall et al., 1995). 
Furthermore, the Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-
Analysis Collaboration Group presented a systematic review and meta-analysis of individual 
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patient data (IPD) from eighteen trials with 2,074 patients. (Neoadjuvant Chemotherapy for 
Locally Advanced Cervical Cancer Meta-analysis Collaboration,2003). Neoadjuvant 
chemotherapy before radiation therapy was compared with radiation therapy alone. The result 
did not show any benefit in overall survival with neoadjuvant chemotherapy. However, when 
the analyses were re-grouped by the interval and the dose intensity of the chemotherapy, a 
survival benefit was apparent in patients who received weekly and biweekly cisplatin with a 
dose of intensity more than 25 mg/m2/week (Table 1). There was 7% absolute improvement in 
overall 5-year survival in trials using shorter cycles of neoadjuvant chemotherapy of less than 
fourteen days. This advantage was also observed in disease-free, locoregional disease-free and 
matastasis-free survival. In addition, trials that used a dose more than 25 mg/m2/week 
showed an improvement of about 3% in 5-year overall survival. Conversely, in trials that 
administered lower dose of cisplatin (less than 25 kg/m2/week) demonstrated an 11% 
reduction in 5-year overall survival. In the meantime, intervals longer than fourteen days trials 
demonstrated a decrease of 8% in 5-year overall survival. A decrease was also observed in 
disease-free, locoregional disease-free and matastasis-free survival. The benefit from short 
cycle and dose intensive cisplatin-based neoadjuvant chemotherapy prior radiation therapy 
suggested that chemotherapy may effectively control radioresistant cellular clones and 
decrease the chance of surviving tumor cell regrowth.  
 
Trial grouping 
Number 
of trials
Number of 
events/patients
HR  
(95%CI, P value) 
Heterogeneity 
P value 
5-year 
OS (%) 
Interval of 
chemotherapy (days)
     
>14 11 639/1214 1.25(1.07-1.46), 0.005 0.238  8 
14 6 417/812 0.76(0.62-0.92), 0.005 0.193  7 
Neoadjuvant 
cisplatin dose 
intensity (mg/m2) 
 
    
<25 7 413/845 1.35(1.11-1.64), 0.002 0.746  11% 
25 11 671/1229 0.91(0.78-1.05), 0.200 0.001  3% 
Table 1. Overall survival (OS) by frequency of chemotherapy and cisplatin dose intensity in 
comparison I (Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-
analysis Collaboration,2003; Gonzalez-Martin et al., 2008) 
2.2 Neoadjuvant chemotherapy before concurrent chemoradiation  
Studies on neoadjuvant chemotherapy before concurrent chemoradiation is limited. 
Gonzalez et al. (Duenas-Gonzalez et al., 2002) reported a phase II study that compared 
neoadjuvant chemotherapy followed by surgery or concurrent chemoradiation with 
standard concomitant chemoradiation. There were two groups, forty-one patients with 
cervical carcinoma in stage IB2-IIIB each, in the study. The first group was treated with 
neoadjuvant chemotherapy. The treatment consisted of cisplatin 100 mg/m2 given on the 
first day and gemcitabine 1,000 mg/m2 given on day 1 and 8, followed by either surgery or 
concomitant chemoradiation, depending on operability. The second group was treated with 
six weekly courses of cisplatin 40 mg/m2 during standard pelvic radiation. Both groups had 
comparable clinicopathological characteristics. In this study, fourteen cases from the first 
group underwent chemoradiation after receiving neoadjuvant chemotherapy. Of these 
patients, thirteen patients had a clinical complete response. Nevertheless, this small number 
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of patients did not conclusively demonstrate a benefit from neoadjuvant chemoradiation 
prior to concurrent chemoradiation. Further research is required to study this approach. 
2.3 Neoadjuvant chemotherapy before surgery 
2.3.1 Neoadjuvant chemotherapy before radical surgery versus radical surgery  
Several studies revealed that giving neoadjuvant chemotherapy before surgery is effective in 
reducing tumor size, expediting micrometastasis treatment, improving operability and 
surgical downstaging (Hwang et al., 2001; Panici et al., 1991; Panici et al., 1991; Sardi et al., 
1993). However, the randomized phase III study from the Gynecologic Oncologic Group 
(GOG) failed to demonstrate a survival benefit when compared to patients who received 
neoadjuvant chemotherapy followed by radical hysterectomy with patients who underwent 
surgery alone for bulky stage IB disease (Eddy et al., 2007). In addition, in a recent Cochrane 
database review, six randomized control trials including 1,072 cervical cancer patients 
comparing neoadjuvant chemotherapy plus surgery with primary surgery showed only 
significantly improvements in progression free survival in the neoadjuvant chemotherapy 
arm. In contrast, overall survival was not improved (Rydzewska et al.,2010).  
Cai et al (2006) reported a randomized study of preoperative chemotherapy versus primary 
radical surgery for stage IB cervical cancer patients. This study was not included in the 
Cochrane review. In the neoadjuvant chemotherapy arm, patients were given cisplatin 75 
mg/m2 on day 1 plus 5- fluorouracil 24 mg/kg/day on day 1-5 every three weeks, for two 
courses. The number of studied patients in the neoadjuvant chemotherapy group was fifty-
two cases, while the patients in primary surgery group numbered fifty-four cases. The 
results demonstrated a reduction in pathological risk factors and an improvement in long-
term survival in patients who received neoadjuvant chemotherapy.  
Another comparative study by Cho et al (2009) compared fifty-one patients who were given 
neoadjuvant chemotherapy before radical hysterectomy with thirty-five patients who received 
radical surgery alone in stage IB2-IIA bulky cervical cancer. Both groups were well balanced in 
age, tumor size, FIGO stage, level of squamous cell cancer antigen, histopathologic type and 
grade, operating time, estimated blood loss, number of lymph nodes removed and rate of 
complications. There was a reduction in pathologic tumor size, and there were fewer patients 
with deep cervical invasion in the neoadjuvant chemotherapy group, and adjuvant radiation 
was given more frequently in the primary surgical group. However, there was no 
improvement in 5-year disease free and overall survival. These findings differed slightly from 
a report from Kim et al (2010). The study expressed the matched - case comparison between 
neoadjuvant chemotherapy before surgery group and primary surgery group in stage IB1-IIA 
and found more definitely reduced intermediate and high risk factors in neoadjuvant 
chemotherapy patients in stage IIA. Although the authors reported no significant difference in 
progression-free survival and disease recurrence between these two studied groups in stage 
IB, the patients who received neoadjuvant chemotherapy before surgery showed worse overall 
survival than the primary surgery group in stage IIA.  
The delay in standard treatment is one important issue of concern in patients receiving 
neoadjuvant chemotherapy. To study this problem, Chen et al (2008) conducted a randomized 
study in stage IB2-IIB comparing modified preoperative neoadjuvant chemotherapy, (N=72) 
with primary radical surgery, (N=70). The neoadjuvant chemotherapy regimen consisted of 
two cycles at fourteen-day intervals of cisplatin 100 mg/m2 IV given on day 1, mitomicin C 4 
mg/m2 IM given on day 1-5 and 5 – fluorouracil 24 mg/kg/day IV given on day 1-5. A 
longer tumor-free survival was observed in the neoadjuvant chemotherapy group. When 
using Cox hazard analysis, however, this did not indicate the therapy modality as a 
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prognostic predictor. The authors further analyzed the survival difference between non-
neoadjuvant chemotherapy responders and the patients in the primary surgery group by 
using Log rank tested. There was no difference in survival between these two groups. 
Therefore, the modified schedule of neoadjuvant chemotherapy did not adversely delay the 
treatment in non-neoadjuvant chemotherapy responders. 
2.3.2 The type of neoadjuvant chemotherapy before surgery  
Many phase II studies have been reported of various neoadjuvant chemotherapy types and 
schedules (table 2). The response rate was over 80% in the studies using combination  
 
Author (year) Chemotherapy Stage N outcome 
Zanetta et al  
(1998) 
Paclitaxel 175 mg/m2 D1& cisplatin 50 mg/m2 
D2-3& ifosfamide 5 gm/m2 D2-3 x 3 courses q 
3 weeks 
IB2-
IVA 
38
Overall RR 
84%,PCR 
16%,PPR 18% 
Sugiyama  
et al (1999)  
Cisplatin 60 mg/m2 day 1-3 & Irinothecan 60 
mg/m2 days 1, 8, 15 x 2-3 courses q 4 weeks 
IB= 
IIIB 
23 CR 13%,PR 65% 
Gonzalez  
et al (2001)  
Cisplatin 100 mg/m2 & gemcitabine 1000 
mg/m2 D1,8 x 2 courses q 3 weeks 
IB2-
IIIB 
41
Overall RR 
95%,PCR 23% 
Gonzalez  
et al (2003)  
Carboplatin AUC=6 & paclitaxel 175 mg/m2 x 
2 courses q 3 weeks 
IB2-
IIIB 
41
63% received 
CCRT,CR 
95%,PCR=17%, 
PPR = 20%, 2 
years OS=79% 
Gonzalez  
et al (2003) 
Oxaliplatin 130 mg/m2 day 1& Gemcitabine 
1250 mg/m2 days 1, 8 x 3 q 3 weeks 
IB-IIB 10 RR 80%, PCR 14% 
Termrungru-
anglert et al 
(2005)  
Cisplatin 70 mg/m2 & gemcitabine 1000 
mg/m2 D1,8 x 2 courses q 3 weeks 
IB2 28
Overall RR 88.9%, 
PCR 8.3%,3 year 
OS = 88.9% 
Suprasert  
et al (2007)  
Cisplatin 75 mg/m2 x 1-2 courses q 3 weeks IB-IIA 42 PR 4.7% 
Bae et al 
(2008)  
cisplatin 60 mg/m2 D1,2 & etoposide 100 
mg/m2 D1 x 3 courses q 10 days 
IB-IIB 99
PRR 69.7%,5-year 
OS 88.1%,5- year 
PFS 60.5% 
Matsumura 
et al (2010)  
Irinotecan 60 mg/m2 D1,8,15 & cisplatin 60 
mg/m2 D1 or Irinotecan 60 mg/m2 D1,8 & 
nadaplatin 80 mg/m2 D1 x 1-2 courses q 4 
weeks  
IB2-
IIB 
46
Overall RR 
80.4%,3- year PFS 
86.1% 
RR = response rate 
CR = complete response 
PR = partial response 
PCR=pathologic complete response 
PPR=pathologic partial response 
PRR = pathologic response rate 
PFS = Progression-free survival rate 
OS = overall survival rate 
CCRT = Concurrent chemoradiation 
Table 2. Phase II study of neoadjuvant chemotherapy followed by radical surgery 
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neoadjuvant chemotherapy (Duenas-Gonzalez et al., 2001; Duenas-Gonzalez et al., 2003; 
Duenas-Gonzalez et al., 2003; Matsumura et al., 2010; Termrungruanglert et al., 2005; 
Sugiyama et al., 1999; Zanetta et al., 1998) but in our study (Suprasert et al., 2007), the 
response rate of using single cisplatin was very low, 4.5%. The pathologic complete response 
was in a range of 8.3-23% (Duenas-Gonzalez et al., 2001; Duenas-Gonzalez et al., 2003; 
Termrungruanglert et al., 2005; Zanetta et al., 1998). Adjuvant radiation was given to 
patients with intermediate and/or high risk factors in most of the studies, except the study 
by Matsumura et al (2010). Chemotherapy was administered in patients with high risk 
factors by using the same regimen as given in the neoadjuvant chemotherapy setting. The 
authors reported the 3-year progression free survival as 86.1%. 
2.4 Neoadjuvant chemotherapy before surgery versus standard radiation therapy  
Benedetti-Panici et al. (2002) conducted an Italian multicenter randomized study comparing 
cisplatin-based neoadjuvant chemotherapy followed by radical surgery versus conventional 
radiotherapy, in locally advance squamous cell cervical cancer. Two hundreds and ten cases 
were assigned to the neoadjuvant chemotherapy group and 199 cases were assigned to the 
conventional radiotherapy group. There was an increase in 5- year overall survival rate for 
patients who received neoadjuvant chemotherapy. However, when analyzed by FIGO stage, 
the overall survival rate significantly increased only in stage IB2 to IIB. In more advanced 
stages, the overall survival rate was not significantly different between the two groups. The 
result suggested that, the more advanced the stage, the more limited the benefit achievable 
by neoadjuvant chemotherapy. This could be explained by considering that the large tumor 
volumes were associated with a large number of hypoxic cells and high proportion of cell 
population in resting phases. Both events reduced chemosensitivity and probability of 
developing resistant clones.  
Another important study (Neoadjuvant Chemotherapy for Locally Advanced Cervical 
Cancer Meta-analysis Collaboration, 2003) was a systematic review and meta-analysis of 
individual patient data from twenty-one randomized trials, which included data from the 
above study (Benedetti-Panici et al., 2002). Two comparisons were performed in the review. 
The first one compared neoadjuvant chemotherapy followed by radiotherapy versus the 
radiotherapy alone as discussed in the previous section (2.1). The other compared 
neoadjuvant chemotherapy followed by surgery with or without radiation versus radical 
radiotherapy. Five randomized trials with a total of 872 patients were analyzed. The 
planned total dose of cisplatin was in a range of 100-300 mg/m2 in 10-21-day cycles while 
the radiation dosage was similar in each trial. The results indicated a highly significant effect 
of neoadjuvant chemotherapy group with overall HR of 0.65 (P=0.00004), which translated 
into an absolute increase in 5-year overall survival rate from 50% to 64%.  
2.5 Neoadjuvant chemotherapy and conservative surgery  
Preoperative neoadjuvant chemotherapy could reduce the tumor size and may virtually 
sterilize micrometastases in the paracervical tissue and pelvic lymph nodes. This effect 
allows for a less extensive surgery of the cervix instead of radical hysterectomy in stage 
IB1patients who desire to preserve fertility-sparing. Maneo et al (2008) reported sixteen 
stage IB1 nulliparous patients treated with three courses of preoperative chemotherapy 
followed by cold-knife conization and pelvic lymphadenectomy. The chemotherapy 
regimen for squamous cell carcinoma consisted of cisplatin 75 mg/m2, paclitaxel 175 mg/m2 
and ifosfamide 5 gm/m2, for adenocarcinoma, epirubicin 80 mg/m2 was applied instead of 
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ifosfamide. During a median follow-up of sixty-nine months, no relapse occurred. However, 
three patients developed carcinoma intraepithelial neoplasia (CIN) after follow- up in long 
term. Regarding the fertility outcome, ten pregnancies occurred in six patients. The authors 
concluded that this integrated treatment was feasible. 
3. Ovarian cancer 
Neoadjuvant chemotherapy was introduced as an alternative management strategy in 
patients with advanced ovarian cancer approximately two decades ago (Chambers et al. 
,1990). Initially, the approach was used only for patients who had significant comorbidities 
and could not tolerate the cytoreductive surgery. Later on, neoadjuvant chemotherapy has 
been advocated for the treatment of the patients with multiple sites of metastases ovarian 
cancer (Ansquer et al., 2001; Schwartz et al., 1999). Other advantages of the neoadjuvant 
chemotherapy approach include a risk reduction of peri-operative morbidity and a higher 
rate of optimal resection than primay debulking surgery (Baekelandt, 2003; Huober et al., 
2002). The optimal resection outcome is an important factor potentially augmenting 
survival rate.  
To review the above issues, three systematic reviews were published (Bristow & Chi, 2006; 
Bristow et al., 2007; Kang & Nam, 2009). The first one was presented in 2007 by Bristow et al 
(Bristow & Chi, 2006). They performed a meta- analysis in twenty-two cohorts studied with 
835 patients in stage III-IV ovarian cancer who received neoadjuvant platinum- base that 
were published in MEDLINE 1989-2005. About 47% of these patients received a taxane. 
They presented the median overall survival of 24.5 months and found that each incremental 
increase in pre-operative chemotherapy cycles was associated with a decrease in median 
survival time of 4.1 months.  
In the subsequent year, they presented a second report (Bristow et al., 2007). In that 
systematic review, they analyzed twenty-six studies published in the English language 
literature encompassing a total of 1,336 patients treated with neoadjuvant chemotherapy. 
The common study design was retrospective analysis in twelve reports, followed by 
retrospective case-control in eight reports, phase I study in four reports, and phase II study 
in the rest. The authors reported that 10 studies showed inferior survival in patients who 
received neoadjuvant chemotherapy compared with primary cytoreductive surgery whereas 
nine studies revealed no significant difference in survival outcome between neoadjuvant 
chemotherapy and primary cytoreductive surgery. With the heterogenous and predominant 
retrospective studies in the systematic review, the authors concluded that neoadjuvant 
chemotherapy should be an alternative management strategy for patients who were felt to 
be non-optimally resectable by an experienced ovarian cancer surgical team.  
The third systematic review was published by Kang et al (2009). Twenty-one studies 
published between January 1989 and June 2008 met the selection criteria. Due to the 
heterogeneity in each study, a meta-regression analysis was implemented. The authors 
found that patients who received neoadjuvant chemotherapy had a lower risk of suboptimal 
cytoreduction than the patients with primary cytoredutive surgery. Meta-regression 
analysis revealed that heterogeneity in year of publication, taxane use, and optimal 
cytoreduction rate influenced median overall survival rate. However, the between- studies 
variation of the number of neoadjuvant chemotherapy cycles did not influence survival. 
This finding disagreed with Bristow’s report. The authors suggested that the contrary result 
was due to the difference in statistical models and the study subjects.  
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In recent years, Vergote et al (2010) presented the large randomized multicenter study of 
stage IIIC or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal 
carcinoma patients treated with neoadjuvant platinum-based chemotherapy followed by 
debulking surgery compared with primary debulking surgery followed by platinum-based 
chemotherapy. Over 300 patients were included in each arm. The results showed a similar 
overall survival and progression – free survival in both groups. However, the optimal 
resection rate was higher in the neoadjuvant chemotherapy arm. On the other hand, the 
postoperative adverse effects and morbidity tended to be higher after primary debulking 
than after received neoadjuvant chemotherapy.  
With respect to elderly patients, McLean et al (2010) reported the comparative study of the 
ovarian cancer patients aged over 65 who received neoadjuvant chemotherapy or primary 
debulking surgery. They found that the overall survival rate did not differ in both 
treatments. The neoadjuvant group showed a trend toward higher rate of optimal debulking 
and less surgical complication than primary surgery group.  
Although many previous reports suggested the non-inferior outcome of neoadjuvant 
chemotherapy setting in advanced ovarian cancer patients, the survey results from 
members of the Society of Gynecologic Oncologists (SGO) revealed that the majority of 
the respondants did not treat patients with neoadjuvant chemotherapy followed by 
interval debulking (Dewdney et al., 2010). The result demonstrated that further research 
would be required to support the role of neoadjuvant chemotherapy in advanced ovarian 
cancer patients.  
4. Endometrial cancer 
Most endometrial cancer patients present at an early stage and are cured with hysterectomy 
and surgical staging alone. The treatment with chemotherapy is predominantly in advanced 
– stage disease which occurs in only 10-15% of all newly diagnosed cases (Behbakht et al., 
1994; Cook et al., 1999). Many studies including a recent meta-analysis demonstrated a 
survival benefit when a small residual volume could be achieved after cytoreductive 
surgery in advanced endometrial cancer (Barlin et al.,2010; Bristow et al., 2000; Chi et al., 
1997; Goff et al., 1994; Memarzadeh et al., 2002; Numazaki et al., 2009). Neoadjuvant 
chemotherapy was of proven benefit in advanced ovarian cancer for increase optimal 
cytoreductive surgery. However, the role of neoadjuvant chemotherapy was still limited 
in advanced endometrial cancer. Vandenput et al.(2009) investigated the value of 
neoadjuvant chemotherapy followed by interval debulking in thirty patients with stage 
IVB endometrial cancer. The most common histology was serous cystadenocarcinoma. 
Over 80% of these patients received paclitaxel plus carboplatin. The number of cycles 
before interval debulking was 3-4 cycles. Six patients (13%) were inoperable due to 
extensive invasion. A total of 22 out of 24 patients (92%) had complete cytoreduction and 
8% had optimal cytoreduction (less than 1 cm). The median progression-free survival and 
overall survival times were 13 and 23 months, respectively. The survival data 
corresponded to the previous reports which treated stage III-IV uterine papillary serous 
carcinoma with primary surgery followed by chemotherapy (Memarzadeh et al, 2002; 
Thomas et al, 2007). The authors suggested that neoadjuvant chemotherapy followed by 
interval cytoreductive surgery was a reasonable option for endometrial cancer with 
thansperitoneal spread. Nevertheless, to support this result, further research on the role of 
neoadjuvant chemotherapy for endometrial cancer is required. 
www.intechopen.com
 
Neoadjuvant Chemotherapy – Current Applications in Clinical Practice 
 
66
5. Vulvar cancer 
Vulvar cancer, an uncommon cancer, represents approximately 4% of all gynecologic 
cancers. The main treatment consists of vulvectomy plus bilateral groin node dissection in 
early stage (de Hullu et al., 2004) and more extensive surgery in locally advanced stage 
(Kehoe, 2006). Although this type of surgery can be curative, it is associated with high 
morbidity and mortality rates. Neoadjuvant chemotherapy is an alternative approach in 
locally advanced vulvar cancer patients. The aim of this strategy is to downstage in an effort 
to avoid the morbidity from such extensive surgery.  
Shimizu et al (1990) published the first related case report using a combination of 
bleomycin, vincristine, mitomicin C and cisplatin for three cycles in an unresectable case 
with FIGO stage IV squamous cell carcinoma of the vulvar. The patient had a complete 
response with few toxic effects and successfully underwent a subsequent radical 
vulvectomy with bilateral groin node dissection. After surgery, the patient was given a 
further two courses of these chemotherapy regimen. She was still free of disease for 20 
months. The next paper was presented by Benedetti-Panici et al (1993). Twenty-one patients 
with locally advanced squamous cell carcinoma of the vulvar received 2-3 courses of 
cisplatin , bleomycin and methotrexate followed by radical surgery in operable patients. Of 
these patients, 10% had a measurable response in the primary tumor and 67% in the groin 
nodes, without serious morbidity. The operability rate following neoadjuvant chemotherapy 
was 90% , but only 79% underwent radical surgery. On the other hand, 3- year survival rate 
was only 24%; 68% of the operated patients recurred 3-17 months after the end of treatment; 
and 50% had a distant relapse. Furthermore, many previous studies reported overall 
response rate of 56% and a poor one year survival rate of 32% with the different 
chemotherapeutic regimen of bleomycin, methotrexate and lomustine (van Doorn et al., 
2006; de Hullu et al., 2004; de Hullu & van der Zee, 2006). In contrast, Geisler et al. (2006) 
reported the very impressive outcome of cisplatin 50 mg/m2 day 1 plus 5-fluorouracil 1,000 
mg/m2 day 1-5 using as neoadjuvant chemotherapy setting in ten patients with advanced 
vulvar cancer involving the anal sphincter and/or urethra. All studied patients underwent 
surgery except one who had a synchronous renal cell carcinoma and died prior to surgery. 
They demonstrated a response rate approaching 100%.  
More recently, to identify the best regimen for this neoadjuvant setting, Domingues et al. 
(2010) analyzed three various neoadjuvant chemotherapy regimens consisting of 20 mg/m2 
continuous perfusion on day 1-10 of bleomycin, 100 mg/m2 of paclitaxel (weekly), and 60-80 
mg/m2 of cisplatin on day 1 plus 750 mg/m2 of 5- fluorouracil on day 1-4 utilized in locally 
advanced vulvar cancer in a 12-year period, to find the best regimen. The best response and 
overall survival rate was associated with using bleomycin. The authors hypothesized the 
contrary results from Geisler’s report that might be from the different of the number of 
studied patients and dosage of chemotherapy.  
To identify the real value of any regimen of neoadjuvant chemotherapy in patients with 
locally advanced vulvar cancer, a large multicenter, and prospective study will ultimately be 
required.  
6. Vaginal cancer 
The data on neoadjuvant chemotherapy in vaginal cancer is limited, due to the rarity of the 
disease. Benedetti Panici et al (2008) reported on eleven patients with stage II vaginal cancer 
who received paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 every three weeks for three 
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courses followed by radical hysterectomy and vaginectomy. Three patients (27%) had a 
complete response and seven patients (64%) experienced a partial clinical response without 
serious toxicity. With a median follow-up time of 75 months, two patients (18%) had disease 
recurrence and one of them died of disease. The authors concluded that neoadjuvant 
chemotherapy followed by radical surgery is a feasible therapeutic strategy with good short 
and long-term results. 
In recent years, case reports of two vaginal cancer patients using different neoadjuvant 
chemotherapy were published. The first one was presented by Takemoto et al (2009). They 
described a 69-year-old woman with stage III primary vaginal adenocarcinoma at recto-
vaginal space. She received neoadjuvant chemotherapy consisting of paclitaxel and 
carboplatin following by pelvic and vaginal radiotherapy. She experienced a complete 
remission and remained free from recurrence one year after treatment. The other case report 
was released by LV et al. (2010). They presented a 41-year-old vaginal cancer patient who 
had a large lesion occupying the entire length of the left latero- posterior vaginal walls with 
left paravaginal tissue involvement. A biopsy showed a poorly differentiated squamous cell 
carcinoma. She was given two courses of bleomycin 15 mg/m2 on day 1-2 and cisplatin 70 
mg/m2 on day1 every fourteen days followed by radical hysterectomy, radical vaginectomy 
and bilateral extraperitoneal pelvic lymphadenectomy. After the resection margins and all 
lymph nodes were confirmed negative by frozen section, vaginal reconstruction with 
bilateral pudendal thigh fasciocutaneous flaps were performed. She received four courses of 
bleomycin and cisplatin chemotherapy postoperatively. At 30 months, the patient was 
clinically free of disease and had a good sexual life.  
7. Conclusion 
In many gynecologic cancers, especially in cervical cancer and ovarian cancer, neoadjuvant 
chemotherapy has been explored to improve the operability and decrease the morbidity of 
radical surgery, without adversely affecting survival. However, research to discover the best 
regimen is still necessary. In some cancers such as in endometrium, vulvar and vagina, there 
are few publications, and further studies are required in the future. 
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